Rating Change
JP Morgan analysts initiated coverage on Neurogene Inc. (NASDAQ:NGNE) with a rating of Overweight on October 08, 2026.
new coverageNASDAQ:NGNE
JP Morgan Initiates Coverage on Neurogene Inc. (NGNE) with Overweight
JP Morgan analysts initiated coverage on Neurogene Inc. (NASDAQ:NGNE) with a rating of Overweight on October 08, 2026.
At publication ·
What changed
Neurogene Inc. (NASDAQ:NGNE) · new coverage
- Firm
- JP Morgan
- Rating
- Overweight
- Price at event
- $26.50
- Market capitalization
- $329.3M
At a glance
Key takeaways
- JP Morgan initiated Overweight coverage on Neurogene Inc. (NGNE) on October 8, 2026, as the healthcare biotech stock trades at $26.50 with a $329.3M market cap.
Market Context
Neurogene Inc. operates in the Healthcare sector. The stock currently trades at $26.50 with a market capitalization of $329.3M.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Neurogene Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Neurogene Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 08, 2026 | JP Morgan | Overweight | N/A |
| Aug 12, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 12, 2026 | Guggenheim | Buy | N/A |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 09, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NGNE Stock Page
Frequently Asked Questions
What does the Overweight rating mean for NGNE?
A rating of Overweight from JP Morgan reflects the analyst's outlook on Neurogene Inc. (NASDAQ:NGNE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NGNE forecast page.